The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Johns Hopkins University - Upcoming Hep C Clinical Studies & Enrollments

Back to News Homepage

Next

Promacta Could Ease Hepatitis C Treatment Complications

Drug Thwarts Hep C Return in Transplanted Livers

November 14, 2011

Print this page

In a phase 2 study, infusions of MassBiologic’s human monoclonal antibody suppressed Hepatitis C resurgence in liver transplant recipients.

Public release date: 7-Nov-2011

Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients

Next step will combine monoclonal antibody with antiviral drugs

San Francisco — A human monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) given to patients with chronic hepatitis C virus (HCV) infection undergoing liver transplantation significantly suppressed the virus for at least a week after transplant and delayed the time to viral rebound. Results from a randomized, double-blind, placebo-controlled, phase 2 study were presented this week at The Liver MeetingĀ®, the annual meeting of the American Association for the Study of Liver Diseases, in San Francisco.

“The challenge for patients with end-stage liver disease from HCV is that a transplant is not a cure. Because the virus remains in the blood stream, the new liver eventually becomes infected with the hepatitis C virus,” said Deborah C. Molrine, MD, deputy director of clinical and regulatory affairs at MassBiologics. “These results show that a human monoclonal antibody targeting the hepatitis C virus can significantly reduce viral loads in infected patients who receive donor livers and moves us one step closer to clearing the virus so the new liver doesn’t become chronically infected.”

Continue reading this entire article:
http://www.eurekalert.org/pub_releases/2011-11/uomm-eds110711.php
Contact: Jim Fessenden
[email protected]
508-856-2000
University of Massachusetts Medical School

No Comments - be the first!
Share
Share

Previous

Johns Hopkins University - Upcoming Hep C Clinical Studies & Enrollments

Back to News Homepage

Next

Promacta Could Ease Hepatitis C Treatment Complications

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.